Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

NCT01827111 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: ABI-007
DRUG: Ipilimumab
BEHAVIORAL: Phone Call

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]